AR and prostate cancer: We used IE1/2 RNAi to assess the effect of CMV inhibition in seven CMV+ prostate cancer cell lines representing CSPC (LNCaP, LAPC‐4, VCaP), AR‐driven/adenocarcinoma CRPC (LNCaP‐abl, LREX’), and non‐AR‐driven CRPC (DU145, PC3).